Roundup Lawsuit 2026: Verdicts, Settlements & Evidence

Roundup Lawsuit 2026: Verdicts, Settlements & Evidence

Roundup Lawsuit 2026: Verdicts, Settlements & Evidence

Roundup Lawsuit 2026: Verdicts, Settlements & Evidence

Can a weedkiller that sits in millions of garden sheds really be at the center of one of the largest product-liability fights in American history? That is the question behind the sprawling Roundup lawsuit litigation. It pits homeowners, farmers, and groundskeepers against Bayer, the German company that bought Monsanto in 2018. The fight has produced billion-dollar jury verdicts, a landmark Supreme Court decision, and a scientific argument that shows no sign of cooling down.

This guide walks through the core allegation, the science on both sides, the verdicts that made headlines, the settlement money, and what anyone weighing a claim should understand before calling a lawyer.

What the Roundup Lawsuit Is Really About

Roundup’s active ingredient is glyphosate. Plaintiffs argue that long-term exposure to glyphosate-based formulas caused non-Hodgkin lymphoma, particularly a subtype called diffuse large B-cell lymphoma. They also argue that Monsanto knew about the risk and failed to warn users. That failure-to-warn theory is the legal engine of most cases. It is not really a claim that Roundup is defective in design. It is a claim that the label did not say enough.

The defendant side tells a different story. Bayer and its supporters point to decades of regulatory review and argue that the product, used as directed, is safe. The company has consistently said the science does not support a cancer link and that the litigation is driven by plaintiff attorneys rather than evidence.

The scale is hard to overstate. By the early 2020s, Bayer reported resolving a large share of more than 100,000 claims, with new suits still being filed. Exact counts change month to month, so any figure you see quoted is a snapshot, not a final tally.

The Science Split That Drives Everything

The Science Split That Drives Everything

Two regulators looked at the same body of research and reached opposite conclusions. That split is the heart of the litigation.

Body Position on glyphosate Year and context
IARC (World Health Organization cancer agency) Classified glyphosate as probably carcinogenic to humans (Group 2A) 2015 monograph, Volume 112
U.S. EPA Found glyphosate not likely to be carcinogenic to humans 2020 interim decision and later reviews
European Union Renewed glyphosate approval for 10 years, through December 2033 November 2023

IARC’s Group 2A label sounds alarming, but it describes hazard, not real-world risk. The category asks whether something could cause cancer under some circumstances, not whether typical exposure does. Critics say that distinction gets lost in headlines. Supporters say the classification reflects genuine warning signs that regulators were too quick to dismiss.

Epidemiological evidence is genuinely mixed. Some meta-analyses have reported a modest increase in non-Hodgkin lymphoma risk tied to high exposure, while other bodies dispute whether that association proves causation. Courts have split on the question too. Some judges let juries hear the plaintiff experts. Others threw out claims, finding the science too weak to support causation. That patchwork is one reason outcomes vary so wildly from courtroom to courtroom.

The Verdicts That Changed the Math

The first major trial set the tone. In August 2018, a San Francisco jury sided with Dewayne “Lee” Johnson, a school groundskeeper, awarding roughly $289 million. The judge later cut that to about $78 million. Johnson became the public face of the litigation, and the verdict stunned the agricultural and chemical industries.

More verdicts followed quickly:

  • Hardeman v. Monsanto (federal court, March 2019): a jury awarded about $80 million, later reduced on appeal. The Ninth Circuit largely upheld liability while trimming damages.

  • Pilliod v. Monsanto (Alameda County, May 2019): a jury returned a verdict that included roughly $2 billion in punitive damages, later reduced by the judge.

  • Dozens of subsequent trials produced a mix of plaintiff wins, defense wins, and reduced awards.

Appellate courts generally let the liability findings stand while shrinking the damage numbers. That pattern matters. It means the legal theory survived review, even as the dollar figures came down. For anyone following the broader question of how product-liability cases play out, the dynamics echo other consumer-goods fights where verdicts and public opinion move in parallel. The same tension between jury sympathy and appellate caution shows up in other high-profile consumer disputes, much as it does in coverage like this iPhone Duo review roundup of what five critics actually said, where the gap between first impressions and lasting verdicts is the whole story.

The $10.9 Billion Settlement Framework

In June 2020, Bayer announced a framework to resolve existing Roundup claims and claims that might arise later, for up to about $10.9 billion, alongside other settlements. The deal was meant to end the litigation. It did not.

Part of the money went to resolving filed cases. Another chunk was set aside for future claims, a structure meant to stop the bleeding. But new plaintiffs kept coming forward, and trials continued. Bayer has since pursued other routes, including lobbying for a federal liability shield and asking the Supreme Court to weigh in on whether federal pesticide labeling rules block state failure-to-warn claims.

That preemption argument is the big legal question. If federal law controls the label, state juries arguably should not be second-guessing it. The company petitioned the Supreme Court in the Hardeman case and lost when the Court denied review in June 2022, leaving the Ninth Circuit ruling in place. In 2025, reports indicated Bayer was trying again through a Missouri case, Monsanto v. Durnell. The status of that petition and any later rulings should be checked against the current Supreme Court docket, since this area moves fast.

Why the Labeling Fight Matters More Than the Science

Here is the counterintuitive part. The Roundup litigation is not mainly a science trial. It is a labeling trial. The central legal question is whether federal pesticide law preempts state-law claims that a warning was missing or inadequate.

If plaintiffs win that argument, every state jury can effectively set its own warning standard. If defendants win, most claims collapse at the courthouse door. That is why so much effort goes into appellate and Supreme Court strategy rather than individual trials. It is also why the regulatory split between the EPA and the EU matters so much. Plaintiffs point to IARC and the EU’s continued approval with conditions. Defendants point to the EPA’s repeated conclusion that glyphosate is not likely carcinogenic.

For readers trying to sort credible claims from noise, the lesson is to check the procedural posture. A jury verdict is not the final word. A settlement is not an admission. A Supreme Court denial is not a ruling on the merits. Each headline captures one slice of a much longer process.

What Anyone Considering a Claim Should Know

Practical experience from these mass-tort cases suggests a few things people get wrong.

First, timing matters. Every state has a statute of limitations. Waiting too long can bar a claim entirely, no matter how strong the facts. Anyone who used Roundup heavily and later received a non-Hodgkin lymphoma diagnosis should get advice promptly rather than sit on it.

Second, exposure records help. Proof of regular, long-term use, ideally with dates, products, and amounts, carries more weight than a vague memory of spraying weeds years ago. Keeping the original containers or purchase records is more useful than most people realize.

Third, not every case qualifies. Mass-tort firms screen heavily for diagnosis type, exposure duration, and documentation. A lymphoma diagnosis alone is not enough. The subtype and the exposure history both matter.

Fourth, settlement structures vary. Some resolutions pay out over time. Others are lump sums. Reading the fine print on fees and timelines matters as much as the headline number, a lesson that applies to any consumer financial decision, from litigation payouts to everyday choices like the ones weighed in this breakdown of money clips, how they work, what they cost and who they suit.

Fifth, be skeptical of guarantees. No honest attorney promises a specific outcome. Anyone who does is selling, not advising.

The Regulatory Picture Beyond the Courtroom

The courtroom fight runs alongside a regulatory one. The EPA’s position has stayed steady through multiple reviews, and the EU renewed glyphosate in November 2023 for a decade, through December 2033, with conditions. That regulatory continuity gives the defense its strongest argument: major regulators looked at the evidence and kept the product on the market.

At the same time, the IARC classification gives plaintiffs their strongest talking point. The two positions are not actually contradictory in a strict sense. One addresses hazard, the other addresses likelihood of cancer under real-world exposure. But in a courtroom, nuance is expensive, and juries respond to stories more than to definitions.

The practical result is a long, grinding litigation with no clean ending. Bayer has spent billions and still faces new cases. Plaintiffs have won huge verdicts and still see them reduced. Regulators have largely held their ground. And the science remains contested at the margins, which is exactly where these cases live.

Conclusion

The Roundup lawsuit is less a single case than a decade-long argument about science, labels, and who gets to decide what a warning should say. The facts are messy on purpose: a cancer agency calls glyphosate probably carcinogenic, a U.S. regulator calls it not likely carcinogenic, and juries keep splitting the difference. Verdicts in the tens of millions and billions have been handed down and then trimmed. A $10.9 billion settlement framework resolved many claims and did not end the fight. A Supreme Court petition failed in 2022, and new legal avenues keep opening.

For anyone touched by this litigation, the takeaways are practical. Document exposure. Move quickly on deadlines. Treat verdict headlines as chapters, not endings. And remember that the biggest legal question, whether federal labeling law blocks state warnings, is still being fought over in courtrooms that most people never hear about.

FAQ

What is the Roundup lawsuit claiming?

Plaintiffs allege that long-term exposure to glyphosate-based Roundup caused non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma, and that Monsanto failed to warn users of the risk. The core legal theory is failure to warn, not that the product was defectively designed.

Has Roundup been proven to cause cancer?

No court or regulator has settled the question definitively. IARC classified glyphosate as probably carcinogenic in 2015, while the EPA has maintained it is not likely carcinogenic. Epidemiological evidence is mixed, and courts have split on whether it supports causation.

How much has Bayer paid out?

Bayer announced a framework in June 2020 to resolve existing claims and claims that might arise later for up to about $10.9 billion. Individual verdicts have ranged from roughly $78 million after reductions in the Johnson case to multibillion-dollar punitive awards later trimmed by judges.

Did the Supreme Court rule on the Roundup cases?

The Supreme Court denied review in the Hardeman case in June 2022, leaving the Ninth Circuit ruling in place. Bayer has since pursued other routes, including a later petition tied to a Missouri case. Anyone tracking the status should check the current Supreme Court docket, since developments continue.

Do I need a lawyer to file a claim?

Yes, in practice. These are complex product-liability cases that require medical records, exposure documentation, and expert evidence. Most firms handling Roundup claims work on contingency, meaning they take a percentage of any recovery rather than charging upfront.

How long do I have to file?

It depends on your state’s statute of limitations, which typically runs from a few months to a few years after diagnosis or discovery. Because deadlines vary and can expire quietly, anyone considering a claim should seek advice promptly rather than wait for the litigation to resolve.

on this page